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ScienceDirectInterleukin-1beta (IL-1b) is a pro-inflammatory cytokine which
is part of the first line innate response in vertebrates and is
induced in injury, infection, and immunity. While temporally
limited induction of IL-1b is believed to protect the organisms
against traumatic or infectious insults, its aberrant expression
in chronic inflammation is detrimental. Therefore,
pharmacological neutralization of IL-1b in chronic inflammatory
diseases is a meaningful strategy to treat inflammation and to
alleviate respective clinical symptoms in man. Canakinumab is
a high-affinity human monoclonal antibody designed to target
human IL-1b in inflammatory diseases. Indeed, canakinumab
has shown excellent efficacy in rare genetic autoinflammatory
diseases or pathological conditions associated with aberrant
production of IL-1b. This review focuses on the molecular and
clinical mode of action and pharmaceutical development of
canakinumab in (auto)inflammatory diseases.
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Introduction
Muckle Wells Syndrome (MWS) and Familial Cold Auto-
inflammatory Syndrome (FCAS) are autosomal dominant
hereditary diseases, and they belong together with the
non-hereditary Neonatal Onset Multisystem Inflamma-
tory Disease/Chronic Infantile Neurologic Cutaneous
and Articular syndrome (NOMID/CINCA) to the family
of Cryopyrin Associated Periodic Syndrome (CAPS).
CAPS is an extremely rare disease with an estimated
prevalence of about 1 per 1,000,000 subjects [1]. The
clinical symptoms in CAPS can be variable; they include
severe fatigue, periodic fever, influenza-like myalgia,
anemia and inflammation of the skin, eyes, bones, joints
and meninges [2]. In 2001, the genetic cause of MWS waswww.sciencedirect.com traced to mutations in the CIAS gene [3,4]. The CIAS1
gene codes for a protein previously termed NALP3, now
NLRP3 [3–5].
At about the same time as the discovery of mutations in
the NLRP3 protein in CAPS, the inflammasome, a regu-
latory protein complex for the production of mature and
bioactive IL-1b was described [6]. Different inflamma-
somes with distinct regulatory subunits exist, which all
converge on caspase I which cleaves pro-IL-1b [7] to
generate its active and secreted form. NLRP3 is a regu-
latory subunit of the NLRP3 inflammasome, and muta-
tions in the NLRP3 gene identified in CAPS patients
render NLRP3 constitutively active (Figure 1). As a
consequence, these NLRP3 mutants are associated with
increased and pathological secretion of IL-1b from pe-
ripheral blood monocytes [8,9].
IL-1b signals through a heterodimeric receptor composed
of IL-1 receptor 1 (IL-1RI) and IL-1 receptor associated
protein (IL-1RacP). Pharmacological treatment of CAPS
with recombinant IL-1 receptor antagonist (IL-Ra), a
competitive antagonist of IL-1 for receptor binding, led
to a rapid and complete clinical and serological response in
a case study with 2 and 3 MWS patients, respectively [9,10].
Preclinical development of canakinumab
Novartis Pharma AG licensed the HuMab-MouseTM
technology from Medarex in the late 1990s and started
a program aimed at the generation of therapeutic human
antibodies targeting human IL-1b. HuMab mice have
part of the human antibody repertoire integrated into
their genome, while their endogenous immunoglobulin
repertoire is inactivated by targeted genetic disruption
[11]. Such mice produce human IgG1 antibodies upon
immunization with antigen, and human monoclonal anti-
bodies can be derived from such mice by conventional
hybridoma technology [12]. Anti-human IL-1b monoclo-
nal antibodies were generated from HuMab mice immu-
nized with human IL-1b antigen. Several different
monoclonal antibodies capable of neutralizing the bioac-
tivity of human IL-1b emerged from this endeavor, and
two of them were progressed into preclinical develop-
ment. The more potent antibody, termed ACZ885, and
later canakinumab, a human IgG1/k antibody, entered
full clinical development.
Canakinumab interacts with human IL-1b with an
equilibrium binding constant of about 40 pM [13] andCurrent Opinion in Chemical Biology 2016, 32:1–9
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Production of mature IL-1b is regulated by the inflammasome. IL-1b production requires two steps: (i) ‘priming’, that is induction of mRNA for pro-
IL-1b via NFkB by for example, toll-like receptor (TLR) signaling and (ii) activation of the inflammasome by the regulatory subunit NLRP3 by a
physiological stimulus (a), or by gain-of-function mutations in CAPS patients (b) [8]. NLRP3 activation leads to multimerization and recruitment of
the adapter protein ASC which enables pro-caspase I to bind to this complex. Autocatalytic cleavage to proteolytically active caspase I is required
for the proteolytic processing of the inactive pro-IL-1b and the secretion of mature and active form of IL-1b [53].neutralizes the biological activity of IL-1b in vitro with
an IC50 of about 43 pM [14]. Canakinumab has high
selectivity towards human IL-1b, it does not bind to other
members of the IL-1 family, including the most related
members IL-1a and IL-1Ra, which both bind also to the
IL-1RI receptor chain. Demonstration of pharmacody-
namic action in vivo was conducted in preclinical mouse
models. To this end, mouse NIH 3T3 cells engineered to
secrete human IL-1b (3T3-hIL-1b) were employed to
induce local inflammatory pathology in the mouse. For
example, neutrophil migration into subcutaneous air-
pouches was initiated by injecting the 3T3-hIL-1b cells
into the airpouch (Dawson et al., unpublished). Systemic
application of canakinumab by intraperitoneal injection
inhibited the neutrophil invasion into the pouch in a dose
dependent manner, demonstrating in vivo potency of this
antibody (Figure 2).
In order to elucidate the molecular mechanism by which
canakinumab interferes with the bioactivity of IL-1b, theCurrent Opinion in Chemical Biology 2016, 32:1–9 crystal structure of canakinumab in complex with IL-1b
was determined [14]. The structural model based on X-
ray diffraction data revealed a large interaction surface of
957 A˚2 for canakinumab, which recognizes an extended,
discontinuous epitope on human IL-1b. All six comple-
mentarity-determining regions are involved in antigen
binding, and 19 residues of canakinumab, 7 contributed
by the light-chain and 12 by the heavy-chain, make
contacts with IL-1b, while 20 residues of IL-1b are in
contact with the antibody. Overlay of the canakinuma-
b:IL-1b structure with the structure of the IL-1b:IL-
1RI:IL-1RacP complex [15,16] revealed that a complex
of canakinumab and IL-1b cannot interact with the IL-1
receptor due to a steric interference between canakinu-
mab VH domain and the D1 domain of IL-1RI. Canaki-
numab does not seem to interfere with the binding of IL-
1RacP, the second component of the IL-1 receptor, to the
IL-1b::IL-1RI complex, as there is no steric overlap with
the respective interaction sites (Figure 3). Therefore,
canakinumab blocks the first step of the assembly ofwww.sciencedirect.com
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Inhibition of polymorphonuclear leucocyte (PMN) influx. Subcutaneous
airpouches were formed by injection of air on the back of OF-1 female
mice, and antibodies or controls were injected intraperitoneally (i.p.)
six days later. The following day, recombinant NIH3T3 cells expressing
human IL-1b were injected into the airpouch, and 24 h later, PMN
numbers were determined in lavage fluid from the airpouch. Data
represent the mean  standard error of the mean from 5 animals per
group (Dawson et al., unpublished data). Controls were animals which
did not receive NIH3T3-IL-1b cells (control), vehicle (saline) and
isotype-matched irrelevant antibody as treatment controls.the active IL-1b receptor complex, binding of IL-1b to
IL-1RI. This structure-based prediction is confirmed by
demonstration of competitive binding to IL-1b between
canakinumab and recombinant soluble IL-1RI and IL-
1RII [14].
Canakinumab exhibits also a very high degree of species
specificity, as it does not bind to mouse, rat or rabbit IL-
1b. Not even the highly related IL-1b from rhesus or
cynomolgus monkeys (96% sequence identity) is recog-
nized by canakinumab. The X-ray structure of canakinu-
mab in complex with IL-1b revealed that Glu64 in human
IL-1b is a critical residue for antibody:antigen interaction.
This residue forms multiple strong interactions with both
heavy and light chain residues of canakinumab, but is not
conserved in macaque monkeys, rodents, canines, and
many other mammalian species [14].
This unusually high species selectivity posed a problem
for the preclinical development of canakinumab, as the
commonly used macaque non-human primates, cynomol-
gus or rhesus monkeys, were not acceptable for toxico-
logical evaluation due to the lack of target binding.
Marmoset monkeys (Callithrix jacchus) belong to the
group of non-human primates, and their physiology is
fairly well characterized [17]. Furthermore, breedingwww.sciencedirect.com colonies for pharmacological testing under good laborato-
ry practice are available. IL-1b from marmoset shares
96% identity with human IL-1b and, most interestingly
for the preclinical development of canakinumab, marmo-
set IL-1b has Glu64 like human IL-1b. Canakinumab
exhibits full crossreactivity to marmoset IL-1b, and the
bioactivity of marmoset IL-1b is effectively neutralized
by canakinumab [14]. Therefore, marmoset monkeys
fulfilled the criteria of a relevant species for toxicological
examination of canakinumab, and the required toxicolog-
ical program for clinical development of canakinumab
could successfully be conducted in this species.
Clinical development
The molecular understanding of the affected cellular
pathway by mutations observed in CAPS patients allows
for the application of a targeted medicine paradigm, that
is specifically and exclusively targeting IL-1b, a highly
potent inflammatory mediator closely downstream of the
causative defect in NLRP3 and the inflammasome. CAPS
is therefore a highly relevant model disease best suited to
unequivocally demonstrate the pharmacokinetic/pharma-
codynamic (PK/PD) relationship and clinical utility of
canakinumab.
Four MWS patients treated by intravenous (i.v.) infusion
of canakinumab at 10 mg/kg showed a fast and complete
clinical, serological, and biochemical response with a
medium duration of 185 days [18]. Complete clinical
responses were subsequently observed in the same
patients upon i.v. infusion of a 10-fold lower dose of
1 mg/kg canakinumab or subcutaneous (s.c.) injection
of 150 mg canakinumab when clinical signs reappeared.
The long duration of clinical remission in CAPS patients
upon administration of a single dose is fully explained by
the pharmacokinetics and potency of canakinumab,
which has a serum half-life of 26 days in CAPS patients
[19]. Clinical development of drugs requires a proper
description of the dose and dose interval to be applied
in the respective patient population. A traditional parallel
arm, placebo-controlled dose finding phase IIb study was
not possible due to the extremely rare prevalence of CAPS.
Therefore, a mathematical model describing the relation-
ship between pharmacokinetics (PK), pharmacodynamics
(PD), target binding (KD), and the production rate of IL-
1b was developed from data collected in this first clinical
phase I/II study in Muckle Wells patients [18].
Pharmacodynamic activity of canakinumab in patients
can be traced by measuring circulating IL-1b in complex
to canakinumab in the serum. The elimination rate of free
IL-1b from blood is very high [20], and steady state
concentrations in blood are therefore extremely low
and hardly measurable in the serum of healthy individuals
or patients [18]. IL-1b in complex to canakinumab has a
much lower rate of elimination, and steady state serum
concentrations of the complex between IL-1b andCurrent Opinion in Chemical Biology 2016, 32:1–9
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Overlay of the X-ray structures of the IL-1b receptor complex consisting of IL-1b (blue surface), IL-1RI (red C-atom backbone), IL-1RacP (green
surface) and the Fab fragment of canakinumab (light chain, light red surface; heavy chain, blue green backbone). The magnified region (insert)
shows the steric overlap between the heavy chain of canakinumab and the D1 domain of IL-1RI. Because of this steric exclusion, only free IL-1b
can form the active receptor complex, and IL-1b complexed to canakinumab cannot bind to IL-1RI. The X-ray structure of the complex between
the canakinumab Fab and IL-1b is described by Rondeau et al. [13].canakinumab can be determined in specific ELISA-
based assays. Measurements of the rate of complex
formation and serum concentrations  of canakinumab
over time and elimination rates of the canakinumab-
IL-1b complex allowed for the generation of a PK/PD
binding model, describing antibody-target complex for-
mation and the distribution of canakinumab into extra-
vascular and serum compartments (Figure 4a). Further
parameters, like the equilibrium binding constant (KD)
for binding to IL-1b, volume of distribution and steady
state tissue concentration of canakinumab are used to
generate a two-compartment PK/PD model [18]. Clini-
cal information, such as the serum concentration of
inflammatory markers, C-reactive protein (CRP) and
the clinical assessment of disease activity in patients
were combined with the PK/PD model. As shown in
Figure 4b, clinical relapse or flare, that is recurrence of
signs and symptoms of disease, is correlated with the
inflammatory serum marker CRP, the model-predictedCurrent Opinion in Chemical Biology 2016, 32:1–9 free IL-1b levels in serum and tissue, the formation of
the complex, and ultimately with the pharmacokinetics
of canakinumab. This model also predicts that the
duration of clinical remission, that is, time to subse-
quent flare, is inversely correlated to the endogenous
production rate of IL-1b in these patients. On the basis
of these correlations, a simpler flare-probability model
was created to link the pharmacokinetics of canakinu-
mab to the probability of clinical relapse, that is a flare,
in MW patients. Basis for such a model were clinical data
obtained from seven MWS patients. These patients
received different doses of canakinumab, ranging be-
tween 1 mg/kg and 10 mg/kg, applied intravenously or
subcutaneously [18]. The duration of clinical response
and the change in CRP over time was recorded, and
patient received re-treatment when clinical signs of a
relapse occurred. The resulting flare-probability model
thereby connected the applied dose of canakinumab to
the change in CRP and the probability of a clinical flare.www.sciencedirect.com
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The dose regimen for canakinumab in CAPS is predicted by a modeling approach. (a) Basis of the PK/PD model. Measured parameters over time
are depicted in brown, and model predicted parameters are represented in blue. The model also incorporates delineated PK parameters, such as
elimination rates, volume of distribution in blood and tissue, equilibrium binding constants, and serum half-life. (b) Time dependent profiles for the
concentration of canakinumab in serum, concentration of the IL-1b:canakinumab complex in plasma, predicted free IL-1b in the central (red) and
peripheral compartment (black), plasma concentration of CRP, and flare probability. Model derived predictions are shown as lines, actual data
from four patients are shown as circles. (c) Withdrawal design of the pivotal phase III study of canakinumab in CAPS. An open label part 1 is
followed by a randomized and double-blind, placebo controlled phase. Patients who completed the part 2 without a clinical relapse and patients
www.sciencedirect.com Current Opinion in Chemical Biology 2016, 32:1–9
6 Next generation therapeuticsMonte Carlo simulations were applied to this flare
probability model, which predicted that a dose regimen
of 150 mg s.c. every 8 weeks would keep the majority of
CAPS patients in clinical remission [18].
The subcutaneous dose regimen of 150 mg every 8 weeks
was tested in a subsequent phase III clinical trial in CAPS
patients [21]. In this three-part, 48-week, double-blind,
placebo-controlled, randomized withdrawal study,
35 patients received first 150 mg of canakinumab. Those
patients who maintained a complete response for 8 weeks
(part 1) entered part 2 and were randomly assigned to
treatment with either canakinumab or placebo every
8 weeks for up to 24 weeks. After the completion of part
2 or at the time of relapse, patients progressed to part
3 and received canakinumab in an open label fashion
(Figure 4c). 34 out of 35 patients enrolled into part 1 of the
study had a complete clinical response to a single dose of
canakinumab. This response was typically observed at
day 8 or day 15 post treatment. 31 patients who main-
tained complete response during part 1 were randomized
to either placebo or canakinumab, which were adminis-
tered every 8 weeks. All 15 patients in the canakinumab
group remained in clinical remission throughout part 2,
while 13 out of 16 patients (81%, p < 0.001) who received
placebo displayed signs of a clinical relapse (Figure 4d).
Results from the this phase III study were confirmed in a
larger open label clinical trial study in which 166 patients
with CAPS were enrolled [22]. Complete clinical re-
sponse to canakinumab was observed in 78% of patients.
Upward dose adjustment is sometimes required for
patients with severe manifestation of disease within
the CAPS spectrum [23]. Other clinical studies confirmed
these initial findings, also reporting improvements in
quality of life measures [24,25]. Canakinumab was well
tolerated, and most adverse events were transient and
mild in nature. Reported adverse events included a
higher incidence of infections in children [22].
Other autoinflammatory diseases
Periodic Fever Syndromes such as Familial Mediterra-
nean Fever (FMF), TNF Receptor Associated Periodic
Syndrome (TRAPS), or Hyper IgD Syndrome (HIDS) are
rare genetic disorders associated with increased produc-
tion of IL-1b from peripheral blood immune cells.
TRAPS and HIDS, like CAPS, are rare and are mostly
confined to Western Europe. FMF is more common and
prevalent around the Mediterranean Sea [26].
The genes and corresponding proteins identified as causal
in these rare genetic disorders are not directly linked to( Figure 4 Legend Continued ) who had a clinical relapse in part 2 received
proportions of patients with a disease flare in part 2 of the pivotal study. All
clinical relapse, while 13 of 16 patient on placebo had a clinical relapse in p
Figure parts a and b were modified based on [18].
Current Opinion in Chemical Biology 2016, 32:1–9 the IL-1b secretion or signaling, except the pyrin protein
in FMF, which interacts with components of the inflam-
masome [27]. TRAPS is caused by mutations in the TNF
receptor I, leading to aberrant folding, intracellular accu-
mulation, stress of the endoplasmic reticulum, and pro-
duction of reactive oxygen which is believed to stimulate
the inflammasome leading to hypersecretion of IL-1b
from peripheral blood monocytes [28]. HIDS is an auto-
somal recessive disorder caused by mutations in meva-
lonate kinase. Deficiency in this enzyme leads to
accumulation of mevalonate, and further downstream
in the pathway to a shortage of isoprenoids [29]. Small
GTPases require modification by isoprenoids for proper
function, and lack of prenylation of the small GTPases
Rac1 and RhoA leads to specific upregulation of IL-1b
mRNA and hypersecretion of IL-1b protein by monocytic
cells [30,31].
Though the molecular defects in FMF, TRAPS and
HIDS are not immediately related to inflammasome
activation like in CAPS, the pathophysiological pathways
in these diseases converge on mechanisms directly linked
to dysregulation and overproduction of IL-1b. Proof of
IL-1b as the causative mediator in these fever syndromes
comes from the clinical use of IL-1-targeted therapy,
including the use of canakinumab. Indeed, FMF, HIDS
and TRAPS patients showed excellent clinical responses
to treatment with canakinumab [32,33,34,35–39,40].
Schnitzler’s syndrome is a chronic autoinflammatory dis-
ease with unknown etiology and manifestation of system-
ic and local inflammation. A genetic cause for this rare
disease has not been identified, but targeted treatment by
blockers of the IL-1 signaling resulted in remarkable
clinical responses [41,42]. A recent study by de Koning
et al. [43] demonstrates increased IL-1b production by
isolated peripheral blood mononuclear cells from Schnit-
zler’s patients in response to lipopolysaccharide, but low
cytokine responses to TLR3 or TLR2/6 agonists. This
finding may point to a selective pathogenic stimulation of
the TLR4 receptor pathway, which is not only responsive
to bacterial lipopolysaccharide, but also to a variety of
endogenous damage-associated molecular pattern mole-
cules (DAMPs). High serum levels of IL-6, a downstream
cytokine to IL-1b, in symptomatic patients and normali-
zation of IL-6 serum concentrations concomitant to a
clinical response upon treatment with canakinumab clear-
ly establish a pathogenic and pivotal role of IL-1b in
Schnitzler’s syndrome.
Systemic Juvenile Idiopathic Arthritis (sJIA) does not
exhibit strong association with dominant or recessive canakinumab treatment. (d) Kaplan–Meier estimates of the
 patients who received canakinumab completed part 2 without a
art 2 of the study. The difference is statistically significant ( p < 0.001).
www.sciencedirect.com
Pharmaceutical development of canakinumab Gram 7gene defects, but cellular and biochemical analysis sug-
gest that sJIA is an autoinflammatory disease rather than
an autoimmune disease [44]. IL-1 and IL-6 have been
demonstrated to play a pivotal role in the pathogenesis of
sJIA, as targeted treatment to either cytokine results in a
dramatic clinical response in the vast majority of sJIA
patients [45,46]. Two phase III trials enrolling patients
with active sJIA were successfully conducted with cana-
kinumab specifically targeting IL-1b. Both trials demon-
strated excellent clinical response rates, good tolerability,
and the ability to taper glucocorticoids in a substantial
fraction of patients [47].
Future directions
Genetic analysis has led to recognition of further auto-
inflammatory hereditary fever syndromes, directly or
indirectly involving inflammasome dysregulation. One
of the latest examples is the identification of mutants
in the NLRC4 inflammasome, leading to overproduction
of IL-1b and autoinflammation, providing a solid ratio-
nale for treating such conditions by IL-1 blockade [48,49].
IL-1b has been found to be involved in a number of
clinically relevant human pathologies, in particular in-
flammatory and vascular disease [50,51]. There are cur-
rently two more drugs approved for CAPS: Rilonacept, a
recombinant soluble IL-1 receptor, and anakinra, the
recombinant IL-1 receptor antagonist, which neutralize
both IL-1a and IL-1b. Canakinumab is the most selec-
tive pharmaceutical agent targeting only IL-1b, and
hence, provides the opportunity to specifically address
the role of IL-1b in human pathology. Indeed, a phase III
clinical testing the hypothesis that neutralization of IL-1b
by canakinumab reduces the risk for subsequent cardio-
vascular events in post myocardial infarction patients is
currently conducted [52]. The underlying pharmacologi-
cal hypothesis for this trial is that IL-1b is a driver of
atherosclerosis and plaque instability in patients with a
high risk for cardiovascular events. It remains to bee seen
if IL-1b is indeed a pivotal mediator of vascular inflam-
mation, and whether neutralization of IL-1b results in a
reduction of cardiovascular events and mortality.
Regulatory status
Canakinumab currently has orphan drug status for CAPS
in the US. The US Food and Drug Agency (FDA) granted
market authorization in June 2009 for the treatment of
FCAS and MWS patients aged four years and older under
the trade name Ilaris1. The European Medicines Agency
(EMA) approved Ilaris1 for the treatment of CAPS,
including NOMID/CINCA in October 2009. Ilaris1 is
currently approved for the treatment of CAPS in about
73 countries worldwide. In addition, Ilaris1 obtained
approval for the treatment of gouty arthritis attacks in
the EU, and it is approved for the treatment of systemic
juvenile idiopathic arthritis (SJIA) in the US and in the
EU.www.sciencedirect.com Conflict of interest statement
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